SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare surges on receiving final approval from USFDA for Tamoxifen Citrate Tablets

30 Oct 2017 Evaluate

Cadila Healthcare is currently trading at Rs. 494.90, up by 3.50 points or 0.71% from its previous closing of Rs. 491.40 on the BSE.

The scrip opened at Rs. 497.00 and has touched a high and low of Rs. 497.00 and Rs. 490.45 respectively. So far 3934 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 329.95 on 26-Dec-2016.

Last one week high and low of the scrip stood at Rs. 502.70 and Rs. 475.00 respectively. The current market cap of the company is Rs. 50306.71 crore.

The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.28% and 7.93% respectively.

Zydus Cadila has received the final approval from the US Food & Drug Administration (USFDA) to market Tamoxifen Citrate Tablets USP in the strengths of 10 mg (base) and 20 mg (base). The drug is indicated to treat breast cancer in women and men and to reduce the incidence of breast cancer in women at high risk for breast cancer.

The tablets will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. The group now has more than 165 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Zydus Lifesciences Share Price

932.05 3.20 (0.34%)
22-Apr-2026 11:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.25
Dr. Reddys Lab 1219.20
Cipla 1230.95
Zydus Lifesciences 932.05
Lupin 2312.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×